RNA could predict cancer recurrence risk. Around a quarter of people with rectal cancer will experience a recurrence of their disease, and knowing the risk could help their monitoring and treatment.
The microRNA (miRNA) diagnostic company Rosetta Genomics ($ROSG) and researchers from Israel have suggested a role for miRNA in predicting the chance of recurrence in these patients. The team looked at the RNA in tumor samples from people with Stage I and Stage II colorectal cancer (cancer that has not spread, or has only spread to nearby organs) who had been treated through surgery. There were no links between the RNA profiles and good or poor outcomes in Stage I disease, but in the more severe Stage II disease, higher levels of miR-29a suggested longer survival without recurrence.
Sign up for our FREE newsletter for more news like this sent to your inbox! - read the abstract - see the press release Related Articles: Urine test could point out colon cancers New biomarker panel could support colorectal cancer diagnosis. PhysOrg Science News: Nanoparticle-delivered RNA... RNA analysis raises hopes of early cancer diagnosis. Expression patterns of microRNAs associated with CML phases and their disease related targets. UofL research shows removal of a tiny RNA molecule can inhibit cancer growth - Life Sciences Social Network.
PDGF induced microRNA alterations in cancer cells - Life Sciences Social Network. "By luck, I stumbled upon your site, and of course I wanted to try it out.
I went on to deposit $500 on OneTwoTrade, then opened 5 positions and won 4. Took out the $500 and still have the profit of $288 to trade with. This is a great system you got there Sir, I definitely owe you one. " Shelly Green - New York "I began with $200 on OneTwoTrade and I went down to $100 the first day. John Bates - Los Angeles "I didn't know what to think about this system at first, as I have always looked at trading as too complicated and only for professionals... obviously I was wrong. PiRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells - Life Sciences Social Network. MiRNA-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3 - Life Sciences Social Network. Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy - Life Sciences Social Network.
BioPortfolio Cancer: BioPortfolio News Overexpr... BioPortfolio Cancer: BioPortfolio News Dicer an... Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients - Life Sciences Social Network. Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway - Life Sciences Social Network. Seq faces a tough road to the cancer clinic. Despite the development of molecular classifications, and prognostic and predictive gene-expression signatures, microarray-based studies have not yielded definitive answers to many of the questions that remain germane for the successful implementation of personalized medicine.
Similar challenges are likely to be encountered in translating next-generation sequencing data into clinically useful information. Needs Challenges Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients - Life Sciences Social Network. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells - Life Sciences Social Network.
FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines. FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines - Life Sciences Social Network. Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3′ untranslated region. + Author Affiliations *To whom correspondence should be addressed.
Tel: +81 29 861 9464; Fax: +81 29 861 2900; Email: renu-wadhwa@aist.go.jp Correspondence may also be addressed to Chae-Ok Yun. Tel: +82 2 2228 8040; Fax: +82 2 2227 7751; Email: chaeok@yuhs.ac Received December 27, 2010. Revision received April 30, 2011. Accepted May 27, 2011. MicroRNAs (miRNAs) are a class of noncoding small RNAs that act as negative regulators of gene expression. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. RNA Interference and Cancer Therapy. RNA Interference and Cancer Therapy. SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells. Access : Developing therapeutic microRNAs for cancer : Gene Therapy.
Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity.